| # | Title | Journal | Year | Citations |
|---|
| 1 | Vitamin D and Multiple Sclerosis: A Comprehensive Review | Neurology and Therapy | 2018 | 245 |
| 2 | A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood | Neurology and Therapy | 2017 | 211 |
| 3 | Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis | Neurology and Therapy | 2016 | 124 |
| 4 | Alzheimer’s Disease: Epidemiology and Clinical Progression | Neurology and Therapy | 2022 | 113 |
| 5 | Deep Learning and Neurology: A Systematic Review | Neurology and Therapy | 2019 | 101 |
| 6 | Pregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing–Remitting Multiple Sclerosis | Neurology and Therapy | 2014 | 99 |
| 7 | Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies | Neurology and Therapy | 2017 | 96 |
| 8 | A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis | Neurology and Therapy | 2020 | 96 |
| 9 | Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations | Neurology and Therapy | 2019 | 94 |
| 10 | An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform | Neurology and Therapy | 2019 | 83 |
| 11 | Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience | Neurology and Therapy | 2015 | 80 |
| 12 | The Impact of Red Blood Cell Distribution Width and Neutrophil/Lymphocyte Ratio on the Diagnosis of Major Depressive Disorder | Neurology and Therapy | 2016 | 80 |
| 13 | Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management | Neurology and Therapy | 2018 | 73 |
| 14 | Virtual Reality Versus Conventional Treatment of Reaching Ability in Chronic Stroke: Clinical Feasibility Study | Neurology and Therapy | 2012 | 67 |
| 15 | Diagnosing and Treating Depression in Patients with Alzheimer’s Disease | Neurology and Therapy | 2019 | 67 |
| 16 | Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database | Neurology and Therapy | 2017 | 62 |
| 17 | A Systematic Review and Meta-Analysis of the Brief Cognitive Assessment for Multiple Sclerosis (BICAMS) | Neurology and Therapy | 2018 | 62 |
| 18 | Increasing Precision of Clinical Diagnosis of Alzheimer's Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data | Neurology and Therapy | 2017 | 61 |
| 19 | Neurophysiological Markers of Alzheimer’s Disease: Quantitative EEG Approach | Neurology and Therapy | 2019 | 60 |
| 20 | A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis | Neurology and Therapy | 2015 | 59 |
| 21 | Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies | Neurology and Therapy | 2020 | 59 |
| 22 | Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer’s Disease | Neurology and Therapy | 2017 | 58 |
| 23 | Depression Among HIV/AIDS Patients on Highly Active Antiretroviral Therapy in the Southwest Regional Hospitals of Cameroon: A Cross-Sectional Study | Neurology and Therapy | 2017 | 55 |
| 24 | Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate | Neurology and Therapy | 2018 | 55 |
| 25 | The Study of Postmortem Human Synaptosomes for Understanding Alzheimer’s Disease and Other Neurological Disorders: A Review | Neurology and Therapy | 2017 | 54 |
| 26 | Salivary Biomarkers for Alzheimer’s Disease and Related Disorders | Neurology and Therapy | 2019 | 54 |
| 27 | Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers | Neurology and Therapy | 2018 | 50 |
| 28 | Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms—A Narrative Review | Neurology and Therapy | 2021 | 50 |
| 29 | Emerging Immunotherapies for Parkinson Disease | Neurology and Therapy | 2019 | 49 |
| 30 | Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms | Neurology and Therapy | 2019 | 48 |
| 31 | A Narrative Review of the Role of Transthyretin in Health and Disease | Neurology and Therapy | 2020 | 47 |
| 32 | European and American Guidelines for Multiple Sclerosis Treatment | Neurology and Therapy | 2018 | 45 |
| 33 | Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers | Neurology and Therapy | 2015 | 43 |
| 34 | Burden of Migraine in Europe Using Self-Reported Digital Diary Data from the Migraine Buddy© Application | Neurology and Therapy | 2018 | 42 |
| 35 | Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy | Neurology and Therapy | 2020 | 41 |
| 36 | The Humanistic and Economic Burden of Alzheimer's Disease | Neurology and Therapy | 2022 | 41 |
| 37 | Emerging Infection, Vaccination, and Guillain–Barré Syndrome: A Review | Neurology and Therapy | 2021 | 40 |
| 38 | A Review of the Social, Psychological, and Economic Burdens Experienced by People with Spina Bifida and Their Caregivers | Neurology and Therapy | 2013 | 39 |
| 39 | Risk of Adverse Outcomes for Older People with Dementia Prescribed Antipsychotic Medication: A Population Based e-Cohort Study | Neurology and Therapy | 2017 | 39 |
| 40 | Reflections on the Utility of the Retina as a Biomarker for Alzheimer’s Disease: A Literature Review | Neurology and Therapy | 2019 | 39 |
| 41 | Current Directions in Deep Brain Stimulation for Parkinson’s Disease—Directing Current to Maximize Clinical Benefit | Neurology and Therapy | 2020 | 37 |
| 42 | Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study | Neurology and Therapy | 2015 | 36 |
| 43 | A Review on MS-Based Blood Biomarkers for Alzheimer’s Disease | Neurology and Therapy | 2019 | 35 |
| 44 | A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley? | Neurology and Therapy | 2017 | 34 |
| 45 | Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | Neurology and Therapy | 2021 | 34 |
| 46 | Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies | Neurology and Therapy | 2016 | 33 |
| 47 | Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic Comparison of Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand, and Canada | Neurology and Therapy | 2016 | 32 |
| 48 | Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated | Neurology and Therapy | 2018 | 32 |
| 49 | Burden of Migraine in Japan: Results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study | Neurology and Therapy | 2022 | 32 |
| 50 | Post-COVID-19 Syndrome is Rarely Associated with Damage of the Nervous System: Findings from a Prospective Observational Cohort Study in 171 Patients | Neurology and Therapy | 2022 | 32 |
